Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...

DelveInsight's Short-Acting Insulin Market Insights report provides the current and forecast market analysis, individual ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Novo Nordisk's Awiqli, a once-weekly basal insulin icodec, for ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...